The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2022, Номер 66(3)
Опубликована: Май 25, 2022
Annals of Internal Medicine, Год журнала: 2024, Номер 177(2), С. ITC17 - ITC32
Опубликована: Фев. 1, 2024
Immune-related adverse events (irAEs) are toxicities that arise after the administration of monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) in patients with cancer. They can occur at any time initiation ICI treatment, a broad clinical phenotype be organ-specific or systemic. Although most irAEs manifest as mild to moderate signs and symptoms, severe forms lead irreversible organ failure have acute life-threatening presentations. Treatment should tailored specific involved severity. Glucocorticoids first-line treatment for irAEs, immunosuppressants biologics mainly used second-line treatments.
Язык: Английский
Процитировано
23
Cancers, Год журнала: 2024, Номер 16(11), С. 1990 - 1990
Опубликована: Май 24, 2024
Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized contemporary oncology, presenting efficacy in various solid tumors and lymphomas. However, ICIs may potentially overstimulate the system, leading to immune-related adverse events (irAEs). IrAEs affect multiple organs, such as colon, stomach, small intestine, kidneys, skin, lungs, joints, liver, lymph nodes, bone marrow, brain, heart, endocrine glands (e.g., pancreas, thyroid, or adrenal glands), exhibiting autoimmune inflammation. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is commonly used oncology for staging assessment of therapy responses, but it also serve a tool detecting irAEs. This review aims present patterns metabolic activation associated irAEs due ICI treatment, identifiable through 18F-FDG PET/CT. It describes advantages early detection irAEs, presents challenges differentiating them from tumor progression. delves into aspects molecular response within context pseudoprogression hyperprogression, along typical imaging findings related these phenomena. Lastly, summarizes role functional PET oncological immunotherapy, speculating on its future significance limitations.
Язык: Английский
Процитировано
3
European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2023, Номер 50(6), С. 1671 - 1688
Опубликована: Янв. 9, 2023
Abstract Immune checkpoint inhibitors (ICIs) achieve a milestone in cancer treatment. Despite the great success of ICI, ICI therapy still faces big challenge due to heterogeneity tumor, and therapeutic response is complicated by possible immune-related adverse events (irAEs). Therefore, it critical assess systemic immune elicited guide subsequent treatment regimens. Positron emission tomography (PET) molecular imaging an optimal approach diagnosis, effect evaluation, follow-up, prognosis prediction. PET can monitor metabolic changes immunocytes specifically identify immuno-biomarkers reflect responses. Here, we briefly review application date responses following associated rationale.
Язык: Английский
Процитировано
8
European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2023, Номер 50(12), С. 3709 - 3722
Опубликована: Июль 15, 2023
Abstract Aim The development of biomarkers that can reliably and early predict response to immune checkpoint inhibitors (ICIs) is crucial in melanoma. In recent years, the gut microbiome has emerged as an important regulator immunotherapy response, which may, moreover, serve a surrogate marker prognosticator oncological patients under immunotherapy. present study investigate if physiologic colonic [ 18 F]FDG uptake PET/CT before start ICIs correlates with clinical outcome metastatic melanoma patients. relation between lymphoid cell-rich organs long-term patient also assessed. Methodology One hundred nineteen stage IV scheduled for ipilimumab, applied either monotherapy or combination nivolumab, underwent baseline PET/CT. data analysis consisted standardized value (SUV), metabolic tumor volume (MTV), total lesion glycolysis (TLG) calculations colon well measurements colon-to-liver SUV ratios (CLR mean , CLR max ). Visual grading based on four-point scale was performed. Moreover, spleen-to-liver (SLR SLR ) bone marrow-to-liver (BLR BLR were calculated. We measured serum lipopolysaccharide (LPS) levels bacterial translocation mucosal defense homeostasis. results correlated patients’ best progression-free survival (PFS), overall (OS) signs colitis. Results Median follow-up [95%CI] from beginning 64.6 months [61.0–68.6 months]. Best treatment progressive disease (PD) 60 patients, stable (SD) 37 partial (PR) complete (CR) 4 Kaplan–Meier curves demonstrated trend longer PFS OS lower values; however, no statistical significance these parameters prognostic factors demonstrated. On other hand, showing control (SD, PR, CR) had significantly MTV TLG than those PD. With regard organs, observed responding progression treatment. Furthermore, values when dichotomized at their median. multivariate analysis, PET found adversely correlate PFS, OS. Conclusions Physiologic PET/CT, assessed by means SUV, ipilimumab-based does not seem independently volumetric parameters, such TLG, derived normal may identify PFS. investigation glucose metabolism spleen marrow offer information.
Язык: Английский
Процитировано
5
Cancer Biotherapy and Radiopharmaceuticals, Год журнала: 2023, Номер 38(4), С. 225 - 231
Опубликована: Март 24, 2023
Immunotherapy with immune checkpoint inhibitors (ICIs) changed the treatment management in several solid metastatic tumors very poor prognosis, particular melanoma stage IV since its introduction 2011. However, it is not yet fully understood why some patients respond to ICIs and others not, also unclear melanomas are most sensitive ICI treatment. Selection criteria for patient stratification needed approaches under evaluation. These include PD-L1 expression tumor samples, assessment of mutational burden as well radiological molecular imaging techniques, such positron emission tomography (PET)-CT PET-MRI 18F-fluorodeoxyglucose (FDG) or novel radiopharmaceuticals. In near future, a more holistic approach based on combination data sequencing development radiogenomic signatures will be better characterization immunotherapy response selection who benefit from therapy alone chemotherapy.
Язык: Английский
Процитировано
4
European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2023, Номер 50(9), С. 2699 - 2714
Опубликована: Апрель 26, 2023
Abstract Purpose To investigate the prognostic value of [ 18 F]FDG PET/CT as part response monitoring in metastatic melanoma patients treated with immune checkpoint inhibitors (ICIs). Methods Sixty-seven underwent before start treatment (baseline PET/CT), after two cycles (interim PET/CT) and four ICIs administration (late PET/CT). Metabolic evaluation was based on conventional EORTC PERCIST criteria, well newly introduced, immunotherapy-modified PERCIMT, imPERCIST5 iPERCIST criteria. to immunotherapy classified according groups (complete metabolic [CMR], partial [PMR], stable disease [SMD], progressive [PMD]), further dichotomized by rate (responders = [CMR] + [PMR] vs. non-responders [PMD] [SMD]), control (disease [SMD] [PMD]). The spleen-to-liver SUV ratios (SLR mean , SLR max ) bone marrow-to-liver (BLR BLR were also calculated. results correlated patients’ overall survival (OS). Results Median patient follow up [95% CI] 61.5 months [45.3 – 66.7 months]. On interim PET/CT, application novel PERCIMT demonstrated significantly longer for responders, while rest criteria revealed no significant differences between different groups. Respectively late both a trend OS observed responding various immunotherapy-modified. Moreover, lower values OS. Conclusion In PET/CT-based assessment is associated performance modality high first cycles, especially employment addition, investigation spleen glucose metabolism may provide information.
Язык: Английский
Процитировано
4
Research Square (Research Square), Год журнала: 2024, Номер unknown
Опубликована: Фев. 21, 2024
Abstract The aim of the study was to assess healthy tissue metabolism (HTM) using [18F]FDG-PET/CT during chemotherapy in Hodgkin lymphoma (HL) and association HTM with baseline metabolic tumour volume (MTV), haematological parameters, adverse events (AEs), early response progression-free survival (PFS). We retrospectively identified 200 patients advanced HL from RATHL trial PET/CT before (PET0) following 2 cycles (PET2). [18F]FDG-uptake measured bone marrow (BM), spleen, liver mediastinal blood pool (MBP). Deauville score (DS)1-3 used classify responders DS 4-5, non-responders. decreased significantly BM spleen increased MBP at PET2 (all p< 0.0001), but not associated MTV. uptake PET0 lower haemoglobin higher absolute neutrophil counts, platelets white cells. BM, neutropenia after 1-2. treatment failure non-responders had inferior PFS (p = 0.006; hazard ratio 2.31). Change most likely a direct impact rather than change has prognostic value HL.
Язык: Английский
Процитировано
0
Scientific Reports, Год журнала: 2024, Номер 14(1)
Опубликована: Июнь 1, 2024
Abstract The aim of the study was to assess healthy tissue metabolism (HTM) using 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ F]FDG) positron emission tomography/computed tomography (PET/CT) during chemotherapy in Hodgkin lymphoma (HL) and association HTM with baseline metabolic tumour volume (MTV), haematological parameters, adverse events (AEs), early response progression-free survival (PFS). We retrospectively identified 200 patients advanced HL from RATHL trial [ F]FDG-PET/CT before (PET0) following 2 cycles (PET2). F]FDG-uptake measured bone marrow (BM), spleen, liver mediastinal blood pool (MBP). Deauville score (DS) 1–3 used classify responders DS 4–5, non-responders. decreased significantly BM spleen increased MBP at PET2 (all p < 0.0001), but not associated MTV. Higher uptake PET0 lower haemoglobin higher absolute neutrophil counts, platelets, white cells. High BM, neutropenia after 1–2. treatment failure non-responders had inferior PFS ( = 0.023; hazard ratio 2.31). Based on these results, we concluded that change most likely a direct impact rather than has prognostic value HL.
Язык: Английский
Процитировано
0
The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2022, Номер 66(3)
Опубликована: Май 25, 2022
Процитировано
0